112 related articles for article (PubMed ID: 1727208)
1. Serum-soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies.
Pavlidis NA; Manoussakis MN; Germanidis GS; Moutsopoulos HM
Med Pediatr Oncol; 1992; 20(1):26-31. PubMed ID: 1727208
[TBL] [Abstract][Full Text] [Related]
2. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A
Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627
[TBL] [Abstract][Full Text] [Related]
3. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
Srivastava MD; Srivastava A; Srivastava BI
Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Barak V; Ginzburg M; Kalickman I; Polliack A
Leuk Lymphoma; 1992 Aug; 7(5-6):431-8. PubMed ID: 1493444
[TBL] [Abstract][Full Text] [Related]
5. [The serum levels of soluble interleukin-2 receptor in patients with malignant lymphocytic proliferative disorders].
Xu J; Wang B
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):82-4. PubMed ID: 10921108
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Beguin Y; Lampertz S; De Groote D; Igot D; Malaise M; Fillet G
Leukemia; 1993 Dec; 7(12):2019-25. PubMed ID: 8255102
[TBL] [Abstract][Full Text] [Related]
7. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
8. Soluble interleukin-2 receptor levels in cerebrospinal fluid of patients with acute lymphocytic leukemia or with non-Hodgkin's lymphoma.
Chang CS; Liu HW; Lin SF; Chen TP
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 May; 22(2):132-7. PubMed ID: 2605973
[TBL] [Abstract][Full Text] [Related]
9. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
[TBL] [Abstract][Full Text] [Related]
10. Measurement of Soluble Interleukin 2 Receptor in Sera of Adult Patients with Hematological or Solid Malignancies.
Delforge A; Bernier M; Bosmans E; Massy M; Bron D; Heyligen H; Raus J; Mendes Da Costa P; Stryckmans P
Leuk Lymphoma; 1991; 3(5-6):385-93. PubMed ID: 27467429
[TBL] [Abstract][Full Text] [Related]
11. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of CD8 antigen and soluble interleukin 2 receptors in patients with B cell chronic lymphocytic leukemia.
Musolino C; Di Cesare E; Alonci A; Allegra A; Orlando A; Grosso P; Squadrito G
Acta Haematol; 1991; 85(2):57-61. PubMed ID: 1902614
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytes.
Zambello R; Pizzolo G; Trentin L; Agostini C; Chisesi T; Vinante F; Scarselli E; Zanotti R; Vespignani M; De Rossi G
Cancer; 1989 Nov; 64(10):2019-23. PubMed ID: 2804889
[TBL] [Abstract][Full Text] [Related]
14. Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.
Tatsumi M; Sugahara H; Higuchi I; Fukunaga H; Nakamura H; Kanakura Y; Hatazawa J
Int J Clin Oncol; 2009 Apr; 14(2):150-8. PubMed ID: 19390947
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of soluble interleukin-2 receptor (sIL-2R) in B-chronic lymphocytic leukemia.
Cacciola E; Calogero D; Marra G; Guglielmo P
Boll Soc Ital Biol Sper; 1992 Apr; 68(4):259-62. PubMed ID: 1463600
[TBL] [Abstract][Full Text] [Related]
18. Soluble interleukin-2 receptor levels in patients with non-Hodgkin's lymphoma or with acute leukemia.
Chang CS; Lin SF; Liu HW
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1988 May; 21(2):79-84. PubMed ID: 3264231
[TBL] [Abstract][Full Text] [Related]
19. Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies.
Lavabre-Bertrand T; Exbrayat C; Liautard J; Gaillard JP; Baskevitch PP; Poujol N; Duperray C; Bourquard P; Brochier J
Br J Haematol; 1995 Dec; 91(4):871-7. PubMed ID: 8547132
[TBL] [Abstract][Full Text] [Related]
20. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
